Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression
暂无分享,去创建一个
F. Karreth | G. DeNicola | I. I. C. Chio | J. R. Prigge | Aimee Falzone | Y. Kang | E. Schmidt | Nicolas Prieto-Farigua | Janine M. Deblasi | Samantha Caldwell | Janine Deblasi
[1] N. Bardeesy,et al. NRF2 activation induces NADH-reductive stress providing a metabolic vulnerability in lung cancer , 2022, bioRxiv.
[2] J. Simon,et al. TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice , 2022, Oncogene.
[3] M. Pagano,et al. EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion , 2021, Cell.
[4] Donna D. Zhang,et al. The Intricacies of NRF2 Regulation in Cancer. , 2021, Seminars in cancer biology.
[5] Christopher D. McFarland,et al. A functional taxonomy of tumor suppression in oncogenic KRAS-driven lung cancer. , 2021, Cancer discovery.
[6] R. Zhuang,et al. Nrf2 Mediates Metabolic Reprogramming in Non-Small Cell Lung Cancer , 2020, Frontiers in Oncology.
[7] F. Gnad,et al. NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes , 2020, Clinical Cancer Research.
[8] G. DeNicola,et al. Dissecting the Crosstalk between NRF2 Signaling and Metabolic Processes in Cancer , 2020, Cancers.
[9] Masayuki Yamamoto,et al. Microenvironmental Activation of Nrf2 Restricts the Progression of Nrf2-Activated Malignant Tumors , 2020, Cancer Research.
[10] T. Wen,et al. NRF2, a Transcription Factor for Stress Response and Beyond , 2020, International journal of molecular sciences.
[11] Francisco J. Sánchez-Rivera,et al. Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1 , 2020, Nature Cancer.
[12] D. Petrov,et al. Genetic determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo , 2020, bioRxiv.
[13] Yong Zhang,et al. Emerging substrate proteins of Kelch-like ECH associated protein 1 (Keap1) and potential challenges for the development of small-molecule inhibitors of the Keap1-nuclear factor erythroid 2-related factor 2 (Nrf2) protein-protein interaction. , 2020, Journal of medicinal chemistry.
[14] R. Moellering,et al. Photoproximity Profiling of Protein-Protein Interactions in Cells , 2019, bioRxiv.
[15] Matthew E. Ritchie,et al. Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma , 2019, Nature Communications.
[16] B. Ueberheide,et al. Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1 , 2019, Cell.
[17] S. Eriksson,et al. TrxR1, Gsr, and oxidative stress determine hepatocellular carcinoma malignancy , 2019, Proceedings of the National Academy of Sciences.
[18] L. Saso,et al. Pharmacological Applications of Nrf2 Inhibitors as Potential Antineoplastic Drugs , 2019, International journal of molecular sciences.
[19] J. Asara,et al. Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer , 2018, bioRxiv.
[20] Matthew E. Ritchie,et al. Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment. , 2018, Cell metabolism.
[21] H. Motohashi,et al. NRF2 addiction in cancer cells , 2018, Cancer science.
[22] Christopher D. McFarland,et al. Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice , 2018, Nature Genetics.
[23] P. Huppke,et al. Activating de novo mutations in NFE2L2 encoding NRF2 cause a multisystem disorder , 2017, Nature Communications.
[24] M. V. Vander Heiden,et al. Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer , 2017, eLife.
[25] Francisco J. Sánchez-Rivera,et al. Keap1 loss promotes Kras-driven lung cancer and results in a dependence on glutaminolysis , 2017, Nature Medicine.
[26] Ash A. Alizadeh,et al. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. , 2017, Cancer discovery.
[27] Christopher D. McFarland,et al. A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo , 2017, Nature Methods.
[28] Nicolai J. Birkbak,et al. Tracking the Evolution of Non‐Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[29] Peter Bankhead,et al. QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.
[30] J. Cook,et al. Identification and Characterization of MCM3 as a Kelch-like ECH-associated Protein 1 (KEAP1) Substrate* , 2016, The Journal of Biological Chemistry.
[31] Angela N. Brooks,et al. High-throughput Phenotyping of Lung Cancer Somatic Mutations. , 2016, Cancer cell.
[32] T. Shibata,et al. NRF2 Intensifies Host Defense Systems to Prevent Lung Carcinogenesis, but After Tumor Initiation Accelerates Malignant Cell Growth. , 2016, Cancer research.
[33] R. Deberardinis,et al. NRF2 regulates serine biosynthesis in non-small cell lung cancer , 2015, Nature Genetics.
[34] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[35] Steven J. M. Jones,et al. Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.
[36] M. Sporn,et al. NRF2 and cancer: the good, the bad and the importance of context , 2012, Nature Reviews Cancer.
[37] H. Aburatani,et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. , 2012, Cancer cell.
[38] Michelle F Clasquin,et al. LC-MS data processing with MAVEN: a metabolomic analysis and visualization engine. , 2012, Current protocols in bioinformatics.
[39] B. Sobhian,et al. PALB2 Interacts with KEAP1 To Promote NRF2 Nuclear Accumulation and Function , 2012, Molecular and Cellular Biology.
[40] Scott E. Kern,et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis , 2011, Nature.
[41] S. Biswal,et al. Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. , 2010, Antioxidants & redox signaling.
[42] V. Raman,et al. Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. , 2010, Carcinogenesis.
[43] Stephen G Swisher,et al. Nrf2 and Keap1 Abnormalities in Non–Small Cell Lung Carcinoma and Association with Clinicopathologic Features , 2010, Clinical Cancer Research.
[44] Takafumi Suzuki,et al. Genetic Analysis of Cytoprotective Functions Supported by Graded Expression of Keap1 , 2010, Molecular and Cellular Biology.
[45] N. Yoo,et al. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin , 2010, The Journal of pathology.
[46] Hailong Wu,et al. Loss of Kelch-Like ECH-Associated Protein 1 Function in Prostate Cancer Cells Causes Chemoresistance and Radioresistance and Promotes Tumor Growth , 2010, Molecular Cancer Therapeutics.
[47] G. Evan,et al. Distinct thresholds govern Myc's biological output in vivo. , 2008, Cancer cell.
[48] Tsutomu Ohta,et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy , 2008, Proceedings of the National Academy of Sciences.
[49] Rui Wang,et al. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. , 2008, Biochemical and biophysical research communications.
[50] M. Hannink,et al. PGAM5 tethers a ternary complex containing Keap1 and Nrf2 to mitochondria. , 2008, Experimental cell research.
[51] S. Yokoyama,et al. Different Electrostatic Potentials Define ETGE and DLG Motifs as Hinge and Latch in Oxidative Stress Response , 2007, Molecular and Cellular Biology.
[52] J. Herman,et al. Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer , 2006, PLoS medicine.
[53] T. Jacks,et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. , 2005, Cancer research.
[54] H. Akaza,et al. Nrf2 Is Essential for the Chemopreventive Efficacy of Oltipraz against Urinary Bladder Carcinogenesis , 2004, Cancer Research.
[55] R. DePinho,et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. , 2004, Cancer cell.
[56] J. D. Engel,et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation , 2003, Nature Genetics.
[57] K. Itoh,et al. Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and tumor yield in mice. , 2003, Carcinogenesis.
[58] T. Jacks,et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.
[59] K. Itoh,et al. Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. , 2001, Toxicology and applied pharmacology.
[60] M. Kwak,et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[61] Bridgid E Hast,et al. Molecular and Cellular Pathobiology Cancer-derived Mutations in Keap1 Impair Nrf2 Degradation but Not Ubiquitination , 2022 .
[62] T. Kensler,et al. Nrf2: friend or foe for chemoprevention? , 2010, Carcinogenesis.
[63] J. D. Engel,et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. , 1999, Genes & development.